China Traditional Chinese Medicine : INSIDE INFORMATION RENEWAL OF THE SUPER & SHORT TERM COMMERCIAL PAPER AT THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED

中國中藥 控股 有 限公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 570)

INSIDE INFORMATION

RENEWAL OF THE SUPER & SHORT TERM COMMERCIAL PAPER

AT THE NATIONAL ASSOCIATION OF

FINANCIAL MARKET INSTITUTIONAL INVESTORS

This announcement is made by China Traditional Chinese Medicine Holdings Co. Limited (the "Company", together with its subsidiaries, the "Group") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 14 October 2019 in relation to the completion of the issuance of a super & short term commercial paper (the "Note") in the aggregate principal amount of RMB2.8 billion (the "Announcement"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The board of directors of the Company is pleased to announce that the Company proceeds with the renewal of the issuance (the "Issue") of the Note. On 14 September 2020, the Company completed the Issue of the first tranche of the Note, which involved an aggregate amount of RMB one billion, with a maturity of 270 days and coupon rate of 2.6% per annum. The proceeds from the Issue are intended to be used for the repayment of borrowing of subsidiaries from financial institutions, and as the working capital of the subsidiaries of the Group.

1

A memorandum containing information of the Issue has been disclosed on the website of China Money (http://www.chinamoney.com.cn/) and Shanghai Clearing House (http://www. shclearing.com/).

By Order of the Board

China Traditional Chinese Medicine Holdings Co. Limited

WU Xian

Chairman

Hong Kong, 14 September 2020

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. WU Xian, Mr. WANG Xiaochun and Mr. YANG Wenming are executive Directors; Mr. YANG Shanhua, Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.

2